{
    "organizations": [],
    "uuid": "c89e2f2d57d10d88613de6e71d6dd08a9f5a6667",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/03/02/business-wire-seres-therapeutics-to-host-fourth-quarter-2017-financial-results-and-operational-progress-conference-call-and-webcast-on.html",
    "ord_in_thread": 0,
    "title": "Seres Therapeutics to Host Fourth Quarter Financial and Operational Progress Conference Call and Webcast on March 8, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on March 8, 2018 at 8:00 a.m. ET to discuss fourth quarter 2017 results and provide a general business update.\nTo access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 5092388. To join the live webcast, please visit the “Investors and Media” section of the Seres website at www.serestherapeutics.com .\nA webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days.\nAbout Seres Therapeutics\nSeres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. Seres’ clinical candidate SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate Ulcerative Colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection. For more information, please visit www.serestherapeutics.com . Follow us on Twitter @SeresTx .\nView source version on businesswire.com : http://www.businesswire.com/news/home/20180302005073/en/\nIR or PR Contact:\nSeres Therapeutics\nCarlo Tanzi, Ph.D., 617-203-3467\nHead of Investor Relations and Corporate Communications\nctanzi@serestherapeutics.com\nSource: Seres Therapeutics, Inc.",
    "published": "2018-03-02T15:00:00.000+02:00",
    "crawled": "2018-03-02T15:15:51.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "cambridge",
        "business",
        "wire",
        "seres",
        "therapeutic",
        "inc",
        "nasdaq",
        "mcrb",
        "today",
        "announced",
        "management",
        "host",
        "conference",
        "call",
        "live",
        "audio",
        "webcast",
        "march",
        "et",
        "discus",
        "fourth",
        "quarter",
        "result",
        "provide",
        "general",
        "business",
        "update",
        "access",
        "conference",
        "call",
        "please",
        "dial",
        "domestic",
        "international",
        "reference",
        "conference",
        "id",
        "number",
        "join",
        "live",
        "webcast",
        "please",
        "visit",
        "investor",
        "medium",
        "section",
        "seres",
        "website",
        "webcast",
        "replay",
        "available",
        "seres",
        "website",
        "beginning",
        "approximately",
        "two",
        "hour",
        "event",
        "archived",
        "approximately",
        "day",
        "seres",
        "therapeutic",
        "seres",
        "therapeutic",
        "leading",
        "microbiome",
        "therapeutic",
        "platform",
        "company",
        "developing",
        "novel",
        "class",
        "biological",
        "drug",
        "designed",
        "treat",
        "disease",
        "restoring",
        "function",
        "dysbiotic",
        "microbiome",
        "natural",
        "state",
        "bacterial",
        "diversity",
        "function",
        "imbalanced",
        "seres",
        "lead",
        "program",
        "obtained",
        "breakthrough",
        "therapy",
        "orphan",
        "drug",
        "designation",
        "food",
        "drug",
        "administration",
        "phase",
        "development",
        "multiply",
        "recurrent",
        "difficile",
        "infection",
        "seres",
        "clinical",
        "candidate",
        "successfully",
        "completed",
        "phase",
        "1b",
        "study",
        "patient",
        "ulcerative",
        "colitis",
        "seres",
        "also",
        "developing",
        "first",
        "ever",
        "synthetic",
        "microbiome",
        "therapeutic",
        "candidate",
        "phase",
        "1b",
        "study",
        "patient",
        "primary",
        "difficile",
        "infection",
        "information",
        "please",
        "visit",
        "follow",
        "u",
        "twitter",
        "serestx",
        "view",
        "source",
        "version",
        "http",
        "ir",
        "pr",
        "contact",
        "seres",
        "therapeutic",
        "carlo",
        "tanzi",
        "head",
        "investor",
        "relation",
        "corporate",
        "communication",
        "ctanzi",
        "source",
        "seres",
        "therapeutic",
        "inc"
    ]
}